Research programme: HIV vaccines - BIIR/INSERM-ARNS

Drug Profile

Research programme: HIV vaccines - BIIR/INSERM-ARNS

Alternative Names: anti-CD-40 HIV antibody - BIIR/INSERM-ARNS

Latest Information Update: 19 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baylor Institute for Immunology Research
  • Developer Baylor Institute for Immunology Research; INSERM
  • Class Dendritic cell vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 12 Jan 2015 Preclinical studies in HIV infections in USA (Parenteral)
  • 01 Jan 2007 INSERM-ANRS and Baylor Institute of Immunology Research (BIIR) agree to co-develop HIV vaccines for the treatment of HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top